If You Invested $100 In This Stock 5 Years Ago, You Would Have $300 Today

7/17/24 4:00:21 PM ET

Other Pharmaceuticals

Health Care

Get the next $COR alert in real time by email

Cencora (NYSE:COR) has outperformed the market over the past 5 years by 8.06% on an annualized basis producing an average annual return of 21.25%. Currently, Cencora has a market capitalization of $44.28 billion.

Buying $100 In COR: If an investor had bought $100 of COR stock 5 years ago, it would be worth $264.37 today based on a price of $224.84 for COR at the time of writing.

Cencora's Performance Over Last 5 Years

comp_fig

Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Get the next $COR alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$COR

Date	Price Target	Rating	Analyst
9/18/2024	$275.00 → $245.00	Buy → Neutral	BofA Securities
2/26/2024	$261.00	Outperform	Leerink Partners
1/3/2024	$242.00	Overweight	Barclays
12/14/2023	$213.00	Equal Weight	Wells Fargo
12/14/2021	$162.00 → $170.00	Buy → Neutral	Citigroup
11/26/2021	$136.00 → $170.00	Sector Perform	RBC Capital
11/16/2021		Underweight → Equal-Weight	Barclays
11/16/2021	$158.00 → $170.00	Outperform → Neutral	Credit Suisse

More analyst ratings

$COR
Press Releases

Fastest customizable press release news feed in the world

Cencora Reports Fiscal 2024 Fourth Quarter and Year End Results
Revenue of $79.1 Billion for the Fourth Quarter, a 14.7 Percent Year-Over-Year Increase Fourth Quarter GAAP Diluted EPS of $0.02 and Adjusted Diluted EPS of $3.34 Revenue of $294.0 Billion for Fiscal Year 2024, a 12.1 Percent Year-Over-Year Increase Fiscal Year 2024 GAAP Diluted EPS of $7.53 and Adjusted Diluted EPS of $13.76 Company increases its quarterly dividend by 8 percent Cencora, Inc. (NYSE:COR) today reported that in its fiscal year 2024 fourth quarter ended September 30, 2024, revenue increased 14.7 percent to $79.1 billion. Revenue increased 12.1 percent to $294.0 billion for the fiscal year. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earni
11/6/24 6:35:00 AM ET
$COR
Other Pharmaceuticals
Health Care
Cencora Advances Specialty Leadership Through Acquisition of Retina Consultants of America
Cencora, Inc. (NYSE:COR) today announced that it has entered into a definitive agreement to acquire Retina Consultants of America ("RCA"), a leading management services organization (MSO) of retina specialists, from Webster Equity Partners. "The acquisition of RCA will allow Cencora to broaden our relationships with community providers in a high growth segment and build on our leadership in specialty," said Bob Mauch, President & CEO of Cencora. "With a compelling value proposition for physicians, an impressive leadership team and strong clinical research capabilities, RCA is well-positioned at the forefront of retinal care. We intend to use our leading operational infrastructure to help R
11/6/24 6:30:00 AM ET
$COR
Other Pharmaceuticals
Health Care
Cencora Expands Enterprise Leadership Team with Two Senior Appointments
Francois Mandeville Named Executive Vice President, Strategy and M&A Pawan Verma Appointed Executive Vice President, Chief Data and Information Officer Cencora, Inc. (NYSE:COR) today announced the appointment of Francois Mandeville as Executive Vice President, Strategy and M&A, and Pawan Verma as Executive Vice President, Chief Data and Information Officer. Both leaders will join Cencora's enterprise leadership team, bringing their extensive experience and expertise to help advance the company's pharmaceutical-centric strategy and drive growth for Cencora and its customers. "We're thrilled to welcome Francois and Pawan to Cencora's leadership team," said Bob Mauch, President and Chief Ex
11/4/24 8:30:00 AM ET
$COR
Other Pharmaceuticals
Health Care

Cencora Reports Fiscal 2024 Fourth Quarter and Year End Results
Revenue of $79.1 Billion for the Fourth Quarter, a 14.7 Percent Year-Over-Year Increase Fourth Quarter GAAP Diluted EPS of $0.02 and Adjusted Diluted EPS of $3.34 Revenue of $294.0 Billion for Fiscal Year 2024, a 12.1 Percent Year-Over-Year Increase Fiscal Year 2024 GAAP Diluted EPS of $7.53 and Adjusted Diluted EPS of $13.76 Company increases its quarterly dividend by 8 percent Cencora, Inc. (NYSE:COR) today reported that in its fiscal year 2024 fourth quarter ended September 30, 2024, revenue increased 14.7 percent to $79.1 billion. Revenue increased 12.1 percent to $294.0 billion for the fiscal year. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earni
11/6/24 6:35:00 AM ET
$COR
Other Pharmaceuticals
Health Care
Cencora Announces Date and Time for Fourth Quarter Fiscal 2024 Earnings Release
Cencora, Inc. (NYSE:COR) today announced that it plans to release its results for the Fourth Quarter of Fiscal 2024 on Wednesday, November 6, 2024, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on November 6, 2024. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President & Chief Financial Officer The live call will be webcast via the Company's website at investor.cencora.com. Users are encouraged to log on to the webcast approximately 10 minutes in advance of the scheduled start time of the call. To access the
10/1/24 7:30:00 AM ET
$COR
Other Pharmaceuticals
Health Care
Cencora Reports Fiscal 2024 Third Quarter Results
Revenue of $74.2 billion for the Third Quarter, a 10.9 Percent Increase Year-Over-Year Third Quarter GAAP Diluted EPS of $2.42 and Adjusted Diluted EPS of $3.34 Adjusted Diluted EPS Guidance Range Raised to $13.55 to $13.65 for Fiscal 2024 Cencora, Inc. (NYSE:COR) today reported that in its fiscal year 2024 third quarter ended June 30, 2024, revenue increased 10.9 percent year-over-year to $74.2 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.42 for the third quarter of fiscal 2024 compared to $2.35 in the prior year third quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items desc
7/31/24 6:30:00 AM ET
$COR
Other Pharmaceuticals
Health Care

$COR
Market Insights

Live Market Insights

If You Invested $100 In This Stock 5 Years Ago, You Would Have $300 Today
Cencora (NYSE:COR) has outperformed the market over the past 5 years by 8.06% on an annualized basis producing an average annual return of 21.25%. Currently, Cencora has a market capitalization of $44.28 billion. Buying $100 In COR: If an investor had bought $100 of COR stock 5 years ago, it would be worth $264.37 today based on a price of $224.84 for COR at the time of writing. Cencora's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by an
7/17/24 4:00:21 PM ET
$COR
Other Pharmaceuticals
Health Care
AbbVie Appeals To Supreme Court Over Attorney-Client Privilege In 'Long-Standing' AndroGel Case
AbbVie Inc (NYSE:ABBV) has petitioned the U.S. Supreme Court to protect its corporate records, arguing that a lower court ruling threatens the confidentiality of attorney communications. The pharmaceutical company is seeking to overturn a decision by the 3rd U.S. Circuit Court of Appeals, stating that filing a sham patent-infringement lawsuit could override attorney-client privilege. The case stems from allegations in the Philadelphia federal court where drug wholesalers, including Cencora Inc (NYSE:COR) (formerly AmerisourceBergen) and McKesson Corporation (NYSE:MCK), claim they were overcharged for the testosterone replacement drug AndroGel. Also Read: AbbVie’s Parkinson’s Disease
7/12/24 1:39:05 PM ET
$ABBV
$COR
$MCK
$PRGO
Biotechnology: Pharmaceutical Preparations
Health Care
Other Pharmaceuticals
If You Invested $100 In This Stock 5 Years Ago, You Would Have $200 Today
Cencora (NYSE:COR) has outperformed the market over the past 5 years by 6.78% on an annualized basis producing an average annual return of 19.86%. Currently, Cencora has a market capitalization of $43.81 billion. Buying $100 In COR: If an investor had bought $100 of COR stock 5 years ago, it would be worth $247.56 today based on a price of $222.47 for COR at the time of writing. Cencora's Performance Over Last 5 Years Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time. This article was generated by Benzinga's automated content engine and reviewed by an
7/9/24 2:30:34 PM ET
$COR
Other Pharmaceuticals
Health Care

If You Invested $100 In This Stock 5 Years Ago, You Would Have $300 Today

Cencora's Performance Over Last 5 Years

Chat with this insight

Recent Analyst Ratings for $COR

$COR Press Releases

Fastest customizable press release news feed in the world

Cencora Reports Fiscal 2024 Fourth Quarter and Year End Results

Cencora Advances Specialty Leadership Through Acquisition of Retina Consultants of America

Cencora Expands Enterprise Leadership Team with Two Senior Appointments

$COR Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Cencora downgraded by BofA Securities with a new price target

Leerink Partners initiated coverage on Cencora with a new price target

Barclays initiated coverage on Cencora with a new price target

$COR SEC Filings

Cencora Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

Cencora Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

Cencora Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

$COR Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

President & CEO Mauch Robert P. was granted 38,433 shares and covered exercise/tax liability with 16,715 shares, increasing direct ownership by 70% to 52,814 units (SEC Form 4)

Chief Financial Officer Cleary James F was granted 35,137 shares and covered exercise/tax liability with 16,248 shares, increasing direct ownership by 16% to 137,631 units (SEC Form 4)

Executive Vice President Campbell Elizabeth S was granted 13,177 shares and covered exercise/tax liability with 6,094 shares, increasing direct ownership by 61% to 18,738 units (SEC Form 4)

$COR Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

$COR Leadership Updates

Live Leadership Updates

$COR Financials

Live finance-specific insights

$COR Large Ownership Changes

This live feed shows all institutional transactions in real time.

Durcan Dermot Mark bought $109,290 worth of shares (500 units at $218.58), increasing direct ownership by 2% to 21,876 units (SEC Form 4)

Cencora Expands Enterprise Leadership Team with Two Senior Appointments

Network Wireless Solutions (NWS) Appoints Michael Millegan to Board of Directors

Cencora Reports Fiscal 2024 Fourth Quarter and Year End Results

Cencora Announces Date and Time for Fourth Quarter Fiscal 2024 Earnings Release

Cencora Reports Fiscal 2024 Third Quarter Results

Amendment: SEC Form SC 13G/A filed by Cencora Inc.

Amendment: SEC Form SC 13D/A filed by Cencora Inc.

SEC Form SC 13G/A filed by CoreSite Realty Corporation (Amendment)

$COR Market Insights

Live Market Insights